Congestive heart failure-cell therapy - Angiogene

Drug Profile

Congestive heart failure-cell therapy - Angiogene

Alternative Names: AngioCell™; EPAS1-modified myoblast cell therapy

Latest Information Update: 10 Nov 2006

Price : $50

At a glance

  • Originator Angiogene Inc
  • Class
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 10 Nov 2006 No development reported - Preclinical for Congestive heart failure in Canada (unspecified route)
  • 18 Jun 2003 EPAS1 gene/cell therapy is available for licensing (www.angiogene.com)
  • 17 Jun 2003 Preclinical trials in Congestive heart failure in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top